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Available online 25 November 2014AbstractCitalopram-induced syndrome of inappropriate antidiuretic hormone secretion (SIADH) causing hyponatremia is well documented; however,
severe hyponatremia with small doses has not been previously reported. An 84-year-old woman presented with acute confusion and gait
disturbance of 3e4 days' duration and a 2-day history of vomiting but managed to maintain fluid intake. Seven days earlier she was started on
citalopram 10 mg per day for low mood. On examination, she was euvolemic, drowsy, and confused; her serum sodium level was 100 mmol/L. A
working diagnosis of SIADH was proposed. Citalopram was stopped and the patient was treated over 24 hours with hypertonic saline, which led
to clinical improvement, and she was discharged from the hospital 6 days later with a serum sodium level of 131 mmol/L. This case highlights
that citalopram can cause severe hyponatremia (serum sodium as low as 100 mmol/L), even at a low dose, and that such biochemical abnor-
malities can potentially occur within days of starting therapy. It also raises important questions and learning points about the management of
severe hyponatremia.
Copyright © 2014, Taiwan Society of Emergency Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
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61. Introduction
Depression is common in elderly individuals and warrants
treatment.1 Selective serotonin reuptake inhibitors (SSRIs)
such as citalopram are the first line of pharmacological therapy
for depression and can therefore be regularly prescribed in the
community setting to this group of patients who are at partic-
ular risk of experiencing significant side effects.2 Hypona-
tremia secondary to syndrome of inappropriate antidiuretic
hormone secretion (SIADH) is a well-documented side effect
of citalopram and can present with nonspecific symptoms2,4
potentially going unreported or missed in the community
setting. Severe hyponatremia can cause significant morbidity
and mortality, and can lead to permanent brain damage and
even death in severe cases.2,4 Management of these cases is a
significant burden on secondary care and the correction of
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2211-5587/Copyright © 2014, Taiwan Society of Emergency Medicine. Publishedcorrection itself can cause significant morbidity. There are
case reports of mild to moderate hyponatremia with dosages of
20 mg/day.7 Severe symptomatic hyponatremia with a low dose
of 10 mg/day has not been previously reported.
2. Case report
An 84-year-old woman presented to the medical admissions
unit with acute confusion, gait disturbance for 3e4 days, and a
2-day history of vomiting and lethargy. She had managed to
maintain fluid intake. She had consulted her general physician
7 days earlier because of low mood following the death of her
husband and was started on citalopram 10 mg once a day at
bedtime. She had a history of essential hypertension and no
other comorbidities. In addition to citalopram, the patient had
been taking losartan 50 mg/day for the past 5 years. She was
previously independent and lived alone, and regularly cooked
for family members. She was a lifelong nonsmoker and had
alcohol rarely on social occasions.
On examination there was no evidence of seizure activity,
she was clinically euvolemic, her abbreviated mental test scoreby Elsevier Taiwan LLC. All rights reserved.
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was 14/15. She had bilateral extensor planter reflexes but no
other focal neurology was noted on examination.
On admission to the hospital, blood tests showed levels of
serum sodium of 100 mmol/L, potassium 4.9 mmol/L, creat-
inine 79 mmol/L, urea 4.8 mmol/L, thyroid-stimulating hor-
mone 2.56 m/L, and thyroxine 14.5 pmol/L. Additional tests
taken prior to treatment revealed serum osmolality of
212 mOsm/kg, urine osmolality of 378 mOsm/kg, and urine
sodium of 45 mmol/L. Serum sodium level 11 months earlier
was 136 mmol/L.
In the absence of another cause, severe hyponatremia in this
patient was attributed to the citalopram, which was dis-
continued; the patient was treated over 24 hours with hyper-
tonic saline, which led to clinical improvement. She was
treated with 2L of hypertonic saline 1.8% via a central line to
achieve slow correction of serum sodium levels. After 6 hours,
the serum sodium level was 106 mmol/L. Over 24 hours, the
patient's serum sodium level improved to 117 mmol/L.
By the following day the patient's GCS score was 15/15 and
AMT was 8/10. A computed tomography scan of the brain
showed only age-related degenerative changes. A short syn-
acthen test was normal. She was discharged from the hospital
6 days later with a serum sodium level of 131 mmol/L and was
able to resume living independently at home with occasional
help from her family. She remained off antidepressants and
continued on losartan, and serum sodium level 6 months later
was 136 mmol/L. Fig. 1 shows the trend of serum sodium
levels throughout this period.
3. Discussion
We present a case of severe symptomatic hyponatremia
within 7 days of starting a low dose of citalopram. Citalopram
is a well-documented cause of hyponatremia secondary to
SIADH and the associated neurological consequences
including vomiting, confusion, coma, and seizures.2 A case
report and literature review by Fisher et al2 identified 14 pub-
lished cases that described SIADH associated with citalopram.Fig. 1. Trend of serum sodium. Serum sodium levels in mmol/L; prior to,
through admission, and 6 months after hospital discharge.It highlighted that most cases comprised elderly females and
perhaps surprisingly frequently present within 1 week of the
start of citalopram use. However, the patient in our case report
had severe hyponatremia; a serum sodium of 100 mmol/L was
strikingly low when compared to the 14 case reports reviewed
by Fisher et al2 and the 28 case reports by Australian Drug
Reaction Advisory Committee (ADRAC).3 These two groups
document mean values of 116.8 mmol/L and 121.9 mmol/L,
respectively. Our patient was also on losartan, which can cause
hyponatremia; however, the patient was on losartan for 5 years
prior to admission and was restarted on losartan at discharge
from the hospital and serum sodium level remained normal
after 6 months. There is a theoretical plausibility of interaction
of the two offending drugs but there is no evidence of inter-
action of losartan and citalopram in the literature.
In cases of severe hyponatremia where there is evidence of
cerebral irritation, specifically seizures or coma, correction
with hypertonic saline is indicated.4,6 What is more conten-
tious is the safe rate of correction in order to avoid osmotic
demyelination syndrome (ODS) and how this varies according
to whether the decrease in sodium is acute or chronic. There is
no strong evidence-based guidance on sodium replacement in
severe hyponatremia; most of the management algorithms are
based on clinical experience and expert opinion.8 There is a
general consensus that “chronic” hyponatremia occurs over
>48 hours and in these cases extra care should be taken to
avoid ODS by avoiding hypertonic saline unless there are
severe neurological sequelae and ensuring a rate of correction
as slow as 0.5 mmol/L/hour or at a rate of 8 mmol in 24
hours.4,9,10 The recent expert panel recommendations from
Verbalis et al5 in 2013 stipulate correction of serum sodium by
4e8 mmol/L/day, with a lower goal of 4e6 mmol/L/day if the
risk of ODS is high.7 It is also recommended that serum so-
dium not exceed a limit of 8 mmol/L in any 24-hour period for
high risk of ODS and for normal risk of ODS 10e12 mmol/L
in any 24-hour period.7 Newer vasopressin antagonists such as
conivaptan and tolvaptan have recently been approved by the
United States Food and Drug Authority for clinical use for the
treatment of hyponatremia. This marks a new breakthrough;
however, these substances are not yet seen in everyday clinical
practice, likely because of the issues of overcorrection and
side effects such as thirst following therapy.11
In this case report, the patient reported symptoms that
probably do not constitute severe neurological sequelae
described in published literature; i.e., no seizures or coma,4 and
therefore whether urgent correction with hypertonic saline was
required is questioned. The rate at which the patient's serum
sodium level was corrected, particularly in the second 12 hour
period of her admission, was probably faster, particularly given
that the decrease in sodium almost certainly occurred over >48
hours. This perhaps highlights that monitoring serum sodium
level every 6 hours or 12 hours is insufficient; closer moni-
toring every 2 hours or 3 hours is recommended by some au-
thors.9 Given the close monitoring required to undergo
hypertonic saline treatment, these patients are best managed in
a high-care environment. This case illustrates the importance of
close monitoring of sodium levels in the community after
147R.V. Patil et al. / Journal of Acute Medicine 4 (2014) 145e147initiating citalopram therapy even if it is at a lower dose. This
case also sheds light on the known difficulties in managing
severe hyponatremia present for 48 hours or of unclear
duration with nonspecific symptoms and signs.3
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